{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T23:16:20Z","timestamp":1782515780295,"version":"3.54.5"},"reference-count":95,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medicina Intensiva (English Edition)"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.medine.2022.06.014","type":"journal-article","created":{"date-parts":[[2022,7,12]],"date-time":"2022-07-12T08:35:51Z","timestamp":1657614951000},"page":"508-520","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Treatment of severe multi-drug resistant Pseudomonas aeruginosa infections"],"prefix":"10.1016","volume":"46","author":[{"given":"E.","family":"D\u00edaz Santos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Mora Jim\u00e9nez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"del R\u00edo-Carbajo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Vidal-Cort\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.medine.2022.06.014_bib0005","unstructured":"WHO publishes list of bacteria for which new antibiotics are urgently needed. Available from: https:\/\/www.who.int\/news\/item\/27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed. [Accessed 22 November 2021]."},{"key":"10.1016\/j.medine.2022.06.014_bib0010","unstructured":"ENVIN - HELICS. Available from: https:\/\/hws.vhebron.net\/envin-helics\/. [Accessed 22 November 2021]."},{"key":"10.1016\/j.medine.2022.06.014_bib0015","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","article-title":"Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance","volume":"18","author":"Magiorakos","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.medine.2022.06.014_bib0020","doi-asserted-by":"crossref","first-page":"e169","DOI":"10.1093\/cid\/ciaa1478","volume":"72","author":"Tamma","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.medine.2022.06.014_bib0025","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofab320","article-title":"Ceftolozane\/tazobactam and imipenem\/relebactam cross-susceptibility among clinical isolates of Pseudomonas aeruginosa from patients with respiratory tract infections in ICU and non-ICU wards-SMART United States 2017-2019","volume":"8","author":"Lob","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.medine.2022.06.014_bib0030","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/CCM.0000000000003553","article-title":"A comparison of the mortality risk associated with ventilator-acquired bacterial pneumonia and nonventilator ICU-acquired bacterial pneumonia","volume":"47","author":"Ibn Saied","year":"2019","journal-title":"Crit Care Med"},{"key":"10.1016\/j.medine.2022.06.014_bib0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2019.07.002","article-title":"Antibiotic resistance in Pseudomonas aeruginosa \u2013 mechanisms, epidemiology and evolution","volume":"44","author":"Botelho","year":"2019","journal-title":"Drug Resist Updat"},{"key":"10.1016\/j.medine.2022.06.014_bib0040","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.biotechadv.2018.11.013","article-title":"Antibiotic resistance in Pseudomonas aeruginosa: mechanisms and alternative therapeutic strategies","volume":"37","author":"Pang","year":"2019","journal-title":"Biotechnol Adv"},{"key":"10.1016\/j.medine.2022.06.014_bib0045","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1093\/jac\/dkz147","article-title":"Spanish nationwide survey on Pseudomonas aeruginosa antimicrobial resistance mechanisms and epidemiology","volume":"74","author":"Del Barrio-Tofi\u00f1o","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.medine.2022.06.014_bib0050","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.ajic.2019.08.023","article-title":"International Nosocomial Infection Control Consortium (INICC) report, data summary of 45 countries for 2012-2017: device-associated module","volume":"48","author":"Rosenthal","year":"2020","journal-title":"Am J Infect Control"},{"key":"10.1016\/j.medine.2022.06.014_bib0055","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s10096-021-04363-7","article-title":"Comparative activity of newer \u03b2-lactam\/\u03b2-lactamase inhibitor combinations against Pseudomonas aeruginosa from patients hospitalized with pneumonia in European medical centers in 2020","volume":"41","author":"Sader","year":"2022","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.medine.2022.06.014_bib0060","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.eimc.2020.01.017","article-title":"Characterization of AmpC \u03b2-lactamase mutations of extensively drug-resistant Pseudomonas aeruginosa isolates that develop resistance to ceftolozane\/tazobactam during therapy","volume":"38","author":"Fern\u00e1ndez-Esgueva","year":"2020","journal-title":"Enferm Infecc Microbiol Clin (Engl Ed)"},{"key":"10.1016\/j.medine.2022.06.014_bib0065","doi-asserted-by":"crossref","first-page":"3209","DOI":"10.1093\/jac\/dkaa291","article-title":"Molecular and biochemical insights into the in vivo evolution of AmpC-mediated resistance to ceftolozane\/tazobactam during treatment of an MDR Pseudomonas aeruginosa infection","volume":"75","author":"Arca-Su\u00e1rez","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.medine.2022.06.014_bib0070","doi-asserted-by":"crossref","first-page":"e01117","DOI":"10.1128\/AAC.01117-20","article-title":"Mechanisms of resistance to ceftolozane\/tazobactam in Pseudomonas aeruginosa: results of the GERPA multicenter study","volume":"65","author":"Fournier","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.medine.2022.06.014_bib0075","doi-asserted-by":"crossref","DOI":"10.1128\/aac.02067-21","article-title":"Selection of AmpC \u03b2-lactamase variants and metallo-\u03b2-lactamases leading to ceftolozane\/tazobactam and ceftazidime\/avibactam resistance during treatment of MDR\/XDR Pseudomonas aeruginosa infections","volume":"66","author":"Ruedas-L\u00f3pez","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.medine.2022.06.014_bib0080","article-title":"In vitro activity of the novel siderophore cephalosporin, cefiderocol, in Gram-negative pathogens in Europe by site of infection","author":"Candel","year":"2021","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.medine.2022.06.014_bib0085","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.jgar.2021.06.011","article-title":"In vitro activity of cefiderocol and comparators against isolates of Gram-negative bacterial pathogens from a range of infection sources: SIDERO\u2011WT\u20112014-2018 studies in Spain","volume":"26","author":"Cercenado","year":"2021","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.medine.2022.06.014_bib0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.106026","article-title":"Carbapenemase-producing Pseudomonas aeruginosa in Spain: interregional dissemination of the high-risk clones ST175 and ST244 carrying blaVIM-2, blaVIM-1, blaIMP-8, blaVIM-20 and blaKPC-2","volume":"56","author":"P\u00c9rez-V\u00c1zquez","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.medine.2022.06.014_bib0095","article-title":"Cefiderocol activity against clinical Pseudomonas aeruginosa isolates exhibiting ceftolozane-tazobactam resistance","volume":"8","author":"Simner","year":"2021","journal-title":"Open Forum Infect"},{"key":"10.1016\/j.medine.2022.06.014_bib0100","doi-asserted-by":"crossref","first-page":"668","DOI":"10.37201\/req\/102.2021","article-title":"In vitro activity of imipenem\/relebactam against Gram-negative clinical isolates in two Spanish tertiary hospitals","volume":"34","author":"Pe\u00f1uelas","year":"2021","journal-title":"Rev Esp Quimioter"},{"key":"10.1016\/j.medine.2022.06.014_bib0105","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1093\/jac\/dkaa456","article-title":"Activity of imipenem\/relebactam against Pseudomonas aeruginosa producing ESBLs and carbapenemases","volume":"76","author":"Mushtaq","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.medine.2022.06.014_bib0110","article-title":"Activity of imipenem-relebactam and ceftolozane-tazobactam against carbapenem-resistant Pseudomonas aeruginosa and KPC-producing Enterobacterales","volume":"102","author":"Bail","year":"2021","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.medine.2022.06.014_bib0115","doi-asserted-by":"crossref","first-page":"e02165","DOI":"10.1128\/AAC.02165-19","article-title":"Activity of imipenem-relebactam against a large collection of Pseudomonas aeruginosa clinical isolates and isogenic \u03b2-lactam-resistant mutants","volume":"64","author":"Fraile-Ribot","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.medine.2022.06.014_bib0120","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.1093\/jac\/dkab252","article-title":"Activity of meropenem\/vaborbactam and comparators against Gram-negative isolates from Eastern and Western European patients hospitalized with pneumonia including ventilator-associated pneumonia (2014-19)","volume":"76","author":"Shortridge","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.medine.2022.06.014_bib0125","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.ijid.2021.10.022","article-title":"Antimicrobial activities of ceftazidime\/avibactam, ceftolozane\/tazobactam, imipenem\/relebactam, meropenem\/vaborbactam, and comparators against Pseudomonas aeruginosa from patients with skin and soft tissue infections","volume":"113","author":"Sader","year":"2021","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.medine.2022.06.014_bib0130","doi-asserted-by":"crossref","DOI":"10.1007\/s40265-021-01635-6","article-title":"The epidemiology and pathogenesis and treatment of Pseudomonas aeruginosa infections: an update","author":"Reynolds","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.medine.2022.06.014_bib0135","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2018.3927","article-title":"Development and assessment of risk scores for carbapenem and extensive \u03b2-lactam resistance among adult hospitalized patients with Pseudomonas aeruginosa infection","volume":"1","author":"Tartof","year":"2018","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.medine.2022.06.014_bib0140","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1097\/QCO.0000000000000768","article-title":"Predictors of multidrug resistant Pseudomonas aeruginosa involvement in bloodstream infections","volume":"34","author":"Herrera","year":"2021","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.medine.2022.06.014_bib0145","doi-asserted-by":"crossref","first-page":"298","DOI":"10.37201\/req\/034.2021","article-title":"[A systematic review and expert\u2019s analysis of risk factors of infections in adults due to carbapenem-resistant Pseudomonas aeruginosa or Acinetobacter baumannii in Spain]","volume":"34","author":"Ferrer","year":"2021","journal-title":"Rev Esp Quimioter"},{"key":"10.1016\/j.medine.2022.06.014_bib0150","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1001\/jama.2020.2717","article-title":"Prevalence and outcomes of infection among patients in intensive care units in 2017","volume":"323","author":"Vincent","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.medine.2022.06.014_bib0155","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1017\/ice.2016.174","article-title":"Antimicrobial-Resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2011-2014","volume":"37","author":"Weiner","year":"2016","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1016\/j.medine.2022.06.014_bib0160","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.ajic.2017.09.005","article-title":"The epidemiology of nonventilator hospital-acquired pneumonia in the United States","volume":"46","author":"Giuliano","year":"2018","journal-title":"Am J Infect Control"},{"key":"10.1016\/j.medine.2022.06.014_bib0165","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0095042","article-title":"Gram negative wound infection in hospitalised adult burn patients\u2014systematic review and metanalysis","volume":"9","author":"Azzopardi","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.medine.2022.06.014_bib0170","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.jcf.2019.08.006","article-title":"Changing epidemiology of the respiratory bacteriology of patients with cystic fibrosis-data from the European cystic fibrosis society patient registry","volume":"19","author":"Hatziagorou","year":"2020","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.medine.2022.06.014_bib0175","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1055\/s-0041-1730944","article-title":"Bronchiectasis exacerbations: definitions, causes, and acute management","volume":"42","author":"Perl","year":"2021","journal-title":"Semin Respir Crit Care Med"},{"key":"10.1016\/j.medine.2022.06.014_bib0180","article-title":"Understanding and managing sepsis in patients with cancer in the era of antimicrobial resistance","volume":"8","author":"Gudiol","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.medine.2022.06.014_bib0185","doi-asserted-by":"crossref","first-page":"e02671","DOI":"10.1128\/AAC.02671-16","article-title":"Results from a 13-year prospective cohort study show increased mortality associated with bloodstream infections caused by Pseudomonas aeruginosa compared to other bacteria","volume":"61","author":"Thaden","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.medine.2022.06.014_bib0190","doi-asserted-by":"crossref","DOI":"10.1111\/tid.13186","article-title":"Contribution of specific pathogens to bloodstream infection mortality in neutropenic patients with hematologic malignancies: results from a multicentric surveillance cohort study","volume":"21","author":"Kern","year":"2019","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.medine.2022.06.014_bib0195","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1097\/01.CCM.0000275389.31974.22","article-title":"Optimal management therapy for Pseudomonas aeruginosa ventilator-associated pneumonia: an observational, multicenter study comparing monotherapy with combination antibiotic therapy","volume":"35","author":"Garnacho-Montero","year":"2007","journal-title":"Crit Care Med"},{"key":"10.1016\/j.medine.2022.06.014_bib0200","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1017\/S0950268810003055","article-title":"Multidrug-resistant Pseudomonas aeruginosa bloodstream infections: risk factors and mortality","volume":"139","author":"Tumbarello","year":"2011","journal-title":"Epidemiol Infect"},{"key":"10.1016\/j.medine.2022.06.014_bib0205","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.jhin.2019.06.005","article-title":"Incremental clinical and economic burden of suspected respiratory infections due to multi-drug-resistant Pseudomonas aeruginosa in the United States","volume":"103","author":"Tabak","year":"2019","journal-title":"J Hosp Infect"},{"key":"10.1016\/j.medine.2022.06.014_bib0210","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.1038\/emi.2016.22","article-title":"Mortality attributable to carbapenem-resistant Pseudomonas aeruginosa bacteremia: a meta-analysis of cohort studies","volume":"5","author":"Zhang","year":"2016","journal-title":"Emerg Microbes Infect"},{"key":"10.1016\/j.medine.2022.06.014_bib0215","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1007\/s00134-013-2828-9","article-title":"Clinical outcomes of Pseudomonas aeruginosa pneumonia in intensive care unit patients","volume":"39","author":"Tumbarello","year":"2013","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.medine.2022.06.014_bib0220","first-page":"78","article-title":"Antibiotic selection in the treatment of acute invasive infections by Pseudomonas aeruginosa: guidelines by the Spanish Society of Chemotherapy","volume":"31","author":"Mensa","year":"2018","journal-title":"Rev Esp Quimioter"},{"key":"10.1016\/j.medine.2022.06.014_bib0225","doi-asserted-by":"crossref","first-page":"e00115","DOI":"10.1128\/CMR.00115-20","article-title":"New \u03b2-lactam-\u03b2-lactamase inhibitor combinations","volume":"34","author":"Yahav","year":"2020","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.medine.2022.06.014_bib0230","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1093\/cid\/civ097","article-title":"Ceftolozane\/tazobactam plus metronidazole for complicated intra-abdominal infections in an era of multidrug resistance: results from a randomized, double-blind, phase 3 trial (ASPECT-cIAI)","volume":"60","author":"Solomkin","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.medine.2022.06.014_bib0235","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(14)62220-0","article-title":"Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI)","volume":"385","author":"Wagenlehner","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.medine.2022.06.014_bib0240","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/S1473-3099(19)30403-7","article-title":"Ceftolozane\u2013tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial","volume":"19","author":"Kollef","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.medine.2022.06.014_bib0245","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1007\/s10096-019-03573-4","article-title":"Continuous infusion of ceftolozane\/tazobactam is associated with a higher probability of target attainment in patients infected with Pseudomonas aeruginosa","volume":"38","author":"Pilmis","year":"2019","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.medine.2022.06.014_bib0250","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3390\/antibiotics10010079","article-title":"Ceftolozane-tazobactam combination therapy compared to ceftolozane-tazobactam monotherapy for the treatment of severe infections: a systematic review and meta-analysis","volume":"10","author":"Fiore","year":"2021","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.medine.2022.06.014_bib0255","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1093\/cid\/ciw133","article-title":"Efficacy and safety of ceftazidime-avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infection: Results from a randomized, controlled, double-blind, phase 3 program","volume":"62","author":"Mazuski","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.medine.2022.06.014_bib0260","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1093\/cid\/ciw378","article-title":"Ceftazidime-avibactam versus doripenem for the treatment of complicated urinary tract infections, including acute pyelonephritis: RECAPTURE, a phase 3 randomized trial program","volume":"63","author":"Wagenlehner","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.medine.2022.06.014_bib0265","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S1473-3099(17)30747-8","article-title":"Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial","volume":"18","author":"Torres","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.medine.2022.06.014_bib0270","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1097\/QCO.0000000000000755","article-title":"Continuous versus intermittent infusion of antibiotics in Gram-negative multidrug-resistant infections","volume":"34","author":"Gatti","year":"2021","journal-title":"Curr Opin Infect Dis"},{"key":"10.1016\/j.medine.2022.06.014_bib0275","doi-asserted-by":"crossref","first-page":"993","DOI":"10.3390\/antibiotics10080993","article-title":"Pharmacokinetic\/pharmacodynamic adequacy of novel \u03b2-lactam\/\u03b2-lactamase inhibitors against gram-negative bacterial in critically ill patients","volume":"10","author":"Han","year":"2021","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.medine.2022.06.014_bib0280","doi-asserted-by":"crossref","first-page":"e00779","DOI":"10.1128\/AAC.00779-19","article-title":"Evaluation of the synergy of ceftazidime-avibactam in combination with meropenem, amikacin, aztreonam, colistin, or fosfomycin against well-characterized multidrug-resistant Klebsiella pneumoniae and Pseudomonas aeruginosa","volume":"63","author":"Mikhail","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.medine.2022.06.014_bib0285","doi-asserted-by":"crossref","DOI":"10.1128\/Spectrum.00585-21","article-title":"Time-kill evaluation of antibiotic combinations containing ceftazidime-avibactam against extensively drug-resistant Pseudomonas aeruginosa and their potential role against ceftazidime-avibactam-resistant isolates","volume":"9","author":"Montero","year":"2021","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.medine.2022.06.014_bib0290","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1093\/infdis\/jiz149","article-title":"Ceftazidime-avibactam in combination with fosfomycin: a novel therapeutic strategy against multidrug-resistant Pseudomonas aeruginosa","volume":"220","author":"Papp-Wallace","year":"2019","journal-title":"J Infect Dis"},{"key":"10.1016\/j.medine.2022.06.014_bib0295","doi-asserted-by":"crossref","first-page":"E71","DOI":"10.3390\/antibiotics9020071","article-title":"Clinical experience with ceftazidime-avibactam for the treatment of infections due to multidrug-resistant gram-negative bacteria other than carbapenem-resistant enterobacterales","volume":"9","author":"Vena","year":"2020","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.medine.2022.06.014_bib0300","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2021.106517","article-title":"Effectiveness of ceftazidime-avibactam for the treatment of infections due to Pseudomonas aeruginosa","volume":"59","author":"Corbella","year":"2022","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.medine.2022.06.014_bib0305","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.3390\/antibiotics10091126","article-title":"Review of ceftazidime-avibactam for the treatment of infections caused by Pseudomonas aeruginosa","volume":"10","author":"Daikos","year":"2021","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.medine.2022.06.014_bib0310","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1007\/s40121-021-00507-6","article-title":"Ceftazidime-avibactam for the treatment of serious gram-negative infections with limited treatment options: a systematic literature review","volume":"10","author":"Soriano","year":"2021","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.medine.2022.06.014_bib0315","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/S1473-3099(18)30554-1","article-title":"Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial","volume":"18","author":"Portsmouth","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.medine.2022.06.014_bib0320","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S1473-3099(20)30796-9","article-title":"Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial","volume":"21","author":"Bassetti","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.medine.2022.06.014_bib0325","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S1473-3099(20)30731-3","article-title":"Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial","volume":"21","author":"Wunderink","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.medine.2022.06.014_bib0330","doi-asserted-by":"crossref","first-page":"e00700","DOI":"10.1128\/AAC.00700-17","article-title":"Efficacy of cefiderocol against carbapenem-resistant gram-negative bacilli in immunocompetent-rat respiratory tract infection models recreating human plasma pharmacokinetics","volume":"61","author":"Matsumoto","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.medine.2022.06.014_bib0335","doi-asserted-by":"crossref","DOI":"10.1093\/jacamr\/dlab188","article-title":"Real-life experience with compassionate use of cefiderocol for difficult-to-treat resistant Pseudomonas aeruginosa (DTR-P) infections","volume":"3","author":"Meschiari","year":"2021","journal-title":"JAC Antimicrob Resist"},{"key":"10.1016\/j.medine.2022.06.014_bib0340","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12866-019-1522-7","article-title":"In vitro studies evaluating the activity of imipenem in combination with relebactam against Pseudomonas aeruginosa","volume":"19","author":"Young","year":"2019","journal-title":"BMC Microbiol"},{"key":"10.1016\/j.medine.2022.06.014_bib0345","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02209-16","article-title":"Vitro activity of imipenem-relebactam against gram-negative eskape pathogens isolated by clinical laboratories in the United States in 2015 (results from the smart global surveillance program)","volume":"61","author":"Lob","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.medine.2022.06.014_bib0350","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1093\/cid\/ciz530","article-title":"RESTORE-IMI 1: a multicenter, randomized, doubleblind trial comparing efficacy and safety of imipenem\/relebactam vs colistin plus imipenem in patients with imipenem-nonsusceptible bacterial infections","volume":"70","author":"Motsch","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.medine.2022.06.014_bib0355","article-title":"A Randomized, double-blind, multicenter trial comparing efficacy and safety of imipenem\/cilastatin\/relebactam versus piperacillin\/tazobactam in adults with hospital-acquired or ventilator-associated bacterial pneumonia (RESTORE-IMI 2 study)","author":"Titov","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.medine.2022.06.014_bib0360","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofab554","article-title":"Early Multicenter experience with imipenem-cilastatin-relebactam for multidrug-resistant gram-negative infections","volume":"8","author":"Rebold","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.medine.2022.06.014_bib0365","first-page":"1","article-title":"New beta-lactam\u2013beta-lactamase inhibitor combinations","volume":"34","author":"Yahav","year":"2021","journal-title":"Clin Microbiol"},{"key":"10.1016\/j.medine.2022.06.014_bib0370","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1001\/jama.2018.0438","article-title":"Effect of meropenem-vaborbactam vs piperacillin-tazobactam on clinical cure or improvement and microbial eradication in complicated urinary tract infection: the TANGO I randomized clinical trial","volume":"319","author":"Kaye","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.medine.2022.06.014_bib0375","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s40121-018-0214-1","article-title":"Effect and safety of meropenem-vaborbactam versus best-available therapy in patients with carbapenem-resistant enterobacteriaceae infections: the TANGO II randomized clinical trial","volume":"7","author":"Wunderink","year":"2018","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.medine.2022.06.014_bib0380","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofab371","article-title":"Real-world, multicenter experience with meropenem-vaborbactam for gram-negative bacterial infections including carbapenem-resistant enterobacterales and Pseudomonas aeruginosa","volume":"8","author":"Alosaimy","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.medine.2022.06.014_bib0385","article-title":"European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine)","author":"Paul","year":"2021","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.medine.2022.06.014_bib0390","doi-asserted-by":"crossref","DOI":"10.1093\/jac\/dkab352","article-title":"Current and future perspectives in the treatment of multidrug-resistant Gram-negative infections","volume":"76","author":"Bassetti","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.medine.2022.06.014_bib0395","first-page":"1","article-title":"All-cause mortality rates in adults with carbapenem-resistant Gram-negative bacterial infections: a comprehensive review of pathogen-focused, prospective, randomized, interventional clinical studies","author":"Lodise","year":"2022","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.medine.2022.06.014_bib0400","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2021.106344","article-title":"Systematic review and meta-analysis of in vitro efficacy of antibiotic combination therapy against carbapenem-resistant Gram-negative bacilli","volume":"57","author":"Scudeller","year":"2021","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.medine.2022.06.014_bib0405","doi-asserted-by":"crossref","first-page":"e01764","DOI":"10.1128\/AAC.01764-20","article-title":"Imipenem\/cilastatin\/relebactam alone and in combination against Pseudomonas aeruginosa in the in vitro pharmacodynamic model","volume":"64","author":"Chen","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.medine.2022.06.014_bib0410","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1007\/s00134-021-06506-y","article-title":"Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021","volume":"47","author":"Evans","year":"2021","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.medine.2022.06.014_bib0415","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1177\/1060028020974003","article-title":"A critical evaluation of newer \u03b2-lactam antibiotics for treatment of Pseudomonas aeruginosa infections","volume":"55","author":"Blomquist","year":"2021","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.medine.2022.06.014_bib0420","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1093\/cid\/ciz816","article-title":"Ceftolozane\/tazobactam vs polymyxin or aminoglycoside-based regimens for the treatment of drug-resistant Pseudomonas aeruginosa","volume":"71","author":"Pogue","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.medine.2022.06.014_bib0425","doi-asserted-by":"crossref","DOI":"10.1016\/j.jgar.2022.01.023","article-title":"Ceftolozane-tazobactam versus colistin for the treatment of infections due to drug-resistant Pseudomonas aeruginosa. A multicenter cohort study","author":"Almangour","year":"2022","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.medine.2022.06.014_bib0430","doi-asserted-by":"crossref","first-page":"441","DOI":"10.37201\/req\/006.2021","article-title":"[Utilization study in real clinical practice of ceftolozane\/tazobactam vs aminoglycosides and\/or colistin in the treatment of multirresistant or extremely resistant Pseudomonas aeruginosa]","volume":"34","author":"Pinilla-Rello","year":"2021","journal-title":"Rev Esp Quimioter"},{"key":"10.1016\/j.medine.2022.06.014_bib0435","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.106270","article-title":"Multicenter study of ceftolozane\/tazobactam for treatment of Pseudomonas aeruginosa infections in critically ill patients","volume":"57","author":"Balandin","year":"2021","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.medine.2022.06.014_bib0440","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofy280","article-title":"Ceftolozane-tazobactam for the treatment of multidrug-resistant Pseudomonas aeruginosa infections: a multicenter study","volume":"5","author":"Gallagher","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.medine.2022.06.014_bib0445","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1093\/cid\/cix182","article-title":"Ceftolozane-tazobactam for the treatment of multidrug-resistant Pseudomonas aeruginosa infections: clinical effectiveness and evolution of resistance","volume":"65","author":"Haidar","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.medine.2022.06.014_bib0450","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1093\/cid\/cix014","article-title":"Multicenter evaluation of ceftolozane\/tazobactam for serious infections caused by carbapenem-resistant Pseudomonas aeruginosa","volume":"65","author":"Munita","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.medine.2022.06.014_bib0455","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.ijantimicag.2018.11.001","article-title":"Ceftolozane\/tazobactam for the treatment of serious Pseudomonas aeruginosa infections: a multicentre nationwide clinical experience","volume":"53","author":"Bassetti","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.medine.2022.06.014_bib0460","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1007\/s10096-018-3361-0","article-title":"Ceftolozane\/tazobactam for the treatment of multidrug resistant Pseudomonas aeruginosa: experience from the Balearic Islands","volume":"37","author":"D\u00edaz-Ca\u00f1estro","year":"2018","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.medine.2022.06.014_bib0465","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S1473-3099(16)30004-4","volume":"16","author":"Carmeli","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.medine.2022.06.014_bib0470","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofz522","article-title":"Real-world experience with ceftazidime-avibactam for multidrug-resistant gram-negative bacterial infections","volume":"6","author":"Jorgensen","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.medine.2022.06.014_bib0475","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.jgar.2018.07.010","article-title":"Evaluation of ceftazidime\/avibactam for serious infections due to multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa","volume":"15","author":"Rodr\u00edguez-N\u00fa\u00f1ez","year":"2018","journal-title":"J Glob Antimicrob Resist"}],"container-title":["Medicina Intensiva (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173572722001436?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2173572722001436?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T02:36:07Z","timestamp":1761878167000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2173572722001436"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":95,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S2173572722001436"],"URL":"https:\/\/doi.org\/10.1016\/j.medine.2022.06.014","relation":{},"ISSN":["2173-5727"],"issn-type":[{"value":"2173-5727","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of severe multi-drug resistant Pseudomonas aeruginosa infections","name":"articletitle","label":"Article Title"},{"value":"Medicina Intensiva (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medine.2022.06.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.medin.2022.03.015","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Espa\u00f1a,  S.L.U. and SEMICYUC. All rights reserved.","name":"copyright","label":"Copyright"}]}}